YL201
Sponsors
Medilink Therapeutics (Suzhou) Co. Ltd., MediLink Therapeutics (Suzhou) Co., Ltd., Amgen
Conditions
Advanced Esophageal Squamous Cell CarcinomaAdvanced Solid TumorAdvanced Solid TumorsAdvanced solid tumorsNasopharyngeal CarcinomaNon Small Cell Lung CancerRecurrent or Metastatic Nasopharyngeal CarcinomaSmall Cell Lung Cancer
Phase 1
A Study of YL201 in Patients With Advanced Solid Tumors
RecruitingNCT05434234
Start: 2022-05-25End: 2027-10-06Target: 312Updated: 2025-11-10
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
RecruitingNCT06394414
Start: 2024-04-17End: 2030-04-29Target: 162Updated: 2025-02-24
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
RecruitingNCT06898957
Start: 2025-05-16End: 2031-04-23Target: 200Updated: 2026-02-05
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
RecruitingNCT07208773
Start: 2025-10-29End: 2027-12-31Target: 260Updated: 2025-11-17
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
RecruitingNCT07258979
Start: 2025-11-05End: 2028-05-31Target: 202Updated: 2025-12-02
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Not yet recruitingNCT07407933
Start: 2026-03-01End: 2029-02-01Target: 118Updated: 2026-02-12
A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination with Other Anti-Cancer Therapies in Patients with Advanced Solid Tumors
Not yet recruitingCTIS2025-523742-27-00
Target: 35Updated: 2026-03-18
Phase 3
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
RecruitingNCT06612151
Start: 2024-12-17End: 2030-12-01Target: 438Updated: 2025-02-11
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
RecruitingNCT06629597
Start: 2024-12-31End: 2028-12-01Target: 400Updated: 2025-02-10
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Not yet recruitingNCT07487896
Start: 2026-04-30End: 2028-12-31Target: 440Updated: 2026-03-30